西格列汀(Sitagliptin) - 药物靶点：DPP-4_在研适应症：2型糖尿病，杜氏肌营养不良症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

DIABIT-IS X、RT-001、RT001

+ [2]

靶点

DPP-4

作用方式

抑制剂

作用机制

DPP-4抑制剂(二肽基肽酶IV抑制剂)

治疗领域

内分泌与代谢疾病神经系统疾病遗传病与畸形+ [2]

在研适应症

2型糖尿病杜氏肌营养不良症

非在研适应症

瘢痕

原研机构

Zydus Lifesciences Ltd.

在研机构

Revio Therapeutics LLP

Azurity Pharmaceuticals, Inc.

Zydus Lifesciences Ltd.

非在研机构

Merck Sharp & Dohme SA

中国人民解放军总医院

Merck Sharp & Dohme Corp.

+ [3]

权益机构

Libytec Pharmaceutical SA

Cosmos Health, Inc.

Cana Laboratories

最高研发阶段批准上市

首次获批日期

美国 (2023-10-18),

2型糖尿病

最高研发阶段(中国)终止

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C16H15F6N5O

InChIKeyMFFMDFFZMYYVKS-SECBINFHSA-N

CAS号486460-32-6

关联

43

项与西格列汀相关的临床试验

CTRI/2024/12/077770

/ Not yet recruitingN/A

An open label, randomized, balanced, two treatment, two sequence, two-period, cross-over, single-dose, oral bioequivalence study of Sitagliptin tablets 100 mg, Gliclazide Sustained Release Tablets 60 mg and Metformin Hydrochloride Sustained Release Tablets 500 mg (T) Manufactured by Eris Lifesciences Ltd., India with ALSITA® -M 100 (Sitagliptin 100 mg and Metformin Hydrochloride Extended Release Tablets 500 mg) (R1) Manufactured by Alkem Health Science., India and Diamicron® XR 60 mg (Gliclazide Extended Release Tablet 60 mg) (R2) Manufactured by Serdia Pharmaceuticals (India) Pvt, Ltd., India in normalhealthy, adult human male subjects under fasting condition. - NIL

开始日期2024-12-16

申办/合作机构

Eris Lifesciences Ltd.

NCT06659744

/ CompletedN/AIIT

Emulation of Effects of Injectable Semaglutide on Cardiovascular Outcomes in Individuals With Type 2 Diabetes: SUSTAIN6 Trial

Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

开始日期2024-10-24

申办/合作机构

The Brigham & Women's Hospital, Inc.

NCT06659679

/ CompletedN/AIIT

Emulation of the Effects of Oral Semaglutide on Cardiovascular Outcomes in Individuals With Type 2 Diabetes: PIONEER6 Trial

Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

开始日期2024-10-24

申办/合作机构

The Brigham & Women's Hospital, Inc.

100 项与西格列汀相关的临床结果

登录后查看更多信息

100 项与西格列汀相关的转化医学

登录后查看更多信息

100 项与西格列汀相关的专利（医药）

登录后查看更多信息

3,686

项与西格列汀相关的文献（医药）

2026-09-01·NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Repurposing doxycycline as an adjunct to sitagliptin in type 2 diabetes mellitus: a randomized controlled study on glycemic, inflammatory, and cardiometabolic outcomes

Article

作者: Mahdy, Mohamed Abdelhakim ; Ebrahim, Mohamed H E ; Elkhodary, Noha M ; Abd Elhameed, Ahmed G ; Habba, Eslam ; Hamza, Eman ; Dewidar, Samar A ; Eladaroussay, Mazin M ; Radwan, Kholoud H ; Badawoud, Amal Mohammad ; Zakaria, Hadeer ; Rizk, Kamal A Kamaleldein ; Eltantawy, Nashwa ; El-Sayed, Abeer A ; El-Hanafy, Aya A ; Elshorbagi, Nora ; Khrieba, Mohannad O ; Al-Dhelaan, Reham A ; Erfan, Ibrahim Ali ; El-Hanafy, Doaa A ; El-Khateeb, Eman ; Sami, Haidy M ; Morsy, Ahmed A

Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance, β-cell dysfunction, and chronic low-grade inflammation. Doxycycline exhibits anti-inflammatory properties, suggesting potential benefit as an adjunctive therapy in T2DM. To evaluate the efficacy and safety of adjunctive doxycycline in patients with T2DM receiving sitagliptin. In this randomized controlled trial, 57 patients with T2DM were assigned to receive sitagliptin alone (n = 29) or sitagliptin plus doxycycline (n = 28) for 12 weeks. Glycemic indices, insulin sensitivity measures, lipid profile, cardiometabolic risk indices, and inflammatory markers were assessed before and after treatment. Parametric outcomes were analyzed using analysis of covariance (ANCOVA) adjusted for baseline values, while non-parametric biomarkers were analyzed using Hodges-Lehmann estimators. Multivariable linear regression identified independent determinant of treatment response. Between-group comparisons for secondary outcomes were adjusted using the Benjamini-Hochberg false discovery rate. Both groups showed significant within-group improvements in body weight, glycemic indices, lipid profile, and inflammatory markers (p < 0.05). However, the combination therapy demonstrated superior outcomes. Significant reductions were observed in fasting blood glucose (adjusted mean difference: - 6.20 mg/dL, p = 0.034), fasting insulin (- 2.02 μIU/mL, p = 0.008), HOMA-IR (- 0.83, p < 0.001), and HbA1c (- 1.25%, p < 0.001), along with increased insulin sensitivity (QUICKI: + 0.0086, p < 0.001). Cardiometabolic parameters were also significantly improved, including total cholesterol (- 14.0 mg/dL, p = 0.030), triglycerides (- 11.6 mg/dL, p = 0.007), LDL-C (- 14.4 mg/dL, p < 0.001), and HDL-C (+ 4.8 mg/dL, p = 0.030). Risk indices (AI, CVRI, CRR) showed marked reductions (all p < 0.05). Inflammatory biomarkers were associated with improvements with combination therapy, including reductions in MMP-9 (p = 0.030) and CRP (p = 0.002). Regression analysis identified doxycycline treatment as an independent determinant of improvement in most outcomes, including HbA1c, HOMA-IR, QUICKI, lipid indices, and MMP-9. FDR correction confirmed the robustness of these findings. Correlation analyses revealed strong associations between insulin resistance markers and cardiometabolic indices. Adverse events were mild and comparable between groups. The addition of doxycycline to sitagliptin appears to improve glycemic control, insulin sensitivity, cardiometabolic risk profile, and inflammatory status in T2DM, without increasing adverse effects. These findings are exploratory and should be confirmed in larger trials with longer follow-up. CLINICAL TRIAL IDENTIFIER: NCT06329882.

2026-09-01·Research in Pharmaceutical Sciences

Sitagliptin protects against bile duct ligation-induced cholemic nephropathy in male rats through modulation of inflammation, sestrin2, and the Nrf2/SOD pathway

Article

作者: Jafari, Elham ; Askaripour, Majid ; Akhbari, Mohammad ; Khaksari, Mohammad ; Saberi, Shadan

Background and purpose::

Cholestasis or bile duct ligation (BDL) could develop cirrhosis and may lead to other organ dysfunction, including the kidneys, which is called cholemic nephropathy (CN). Hyperbilirubinemia, bile acid accumulation, renal hypoperfusion, oxidative stress, and inflammation are implicated in the pathogenesis of CN. Sitagliptin is an oral antihyperglycemic drug with anti-inflammatory and anti-oxidative effects. Its effects on CN were unknown.

Experimental approach::

The BDL-induced CN model was performed in 35 male Wistar rats (200-250 g), which were divided into five groups (n = 7) as follows: sham group receiving distilled water as vehicle (sham + Veh), BDL group receiving vehicle (BDL + Veh), and BDL groups receiving sitagliptin at the doses of 10, 50, or 100 mg/kg/day by gavage for 14 days named BDL + Sit 10, BDL + Sit 50, and BDL + Sit 100, respectively. Aspartate transferase, alkaline phosphatase, total bilirubin (T-Bil), renal function biomarkers, creatinine (Cr) clearance, redox system status, TNF-α, and renal histopathology were evaluated.

Findings/Results::

BDL increased serum liver enzymes, T-Bil, Cr, urea, urine Cr, albumin to Cr ratio, and decreased Cr clearance. Also, BDL elevated renal sestrin2, malondialdehyde, TNF-α, renal index, and kidney tissue injury score, while reducing superoxide dismutase (SOD) activity, total antioxidant capacity, and nuclear factor erythroid 2-related factor 2 (Nrf2). Sitagliptin, especially at the low dose, reversed these effects.

Conclusion and implications::

Sitagliptin improved renal injury and function via ameliorating inflammation and oxidative stress by activating the Nrf2/SOD pathway in BDL rats. Sitagliptin might help treat renal complications in cirrhosis and liver diseases.

2026-09-01·VALUE IN HEALTH

Assessment of Carbon Emission Impact of Semaglutide in Patients With Type 2 Diabetes in the United Kingdom Using an Innovative Modeling Approach

Article

作者: Chubb, Barrie ; Rasche, Andreas ; Taneja, Loveleen ; Taylor, Matthew ; Xu, Weiwei ; Sharma, Yuvraj ; Lund, Niels ; Olivieri, Anamaria-Vera

OBJECTIVES:

To evaluate the carbon footprint and clinical outcomes of once-weekly subcutaneous semaglutide in patients with type 2 diabetes mellitus (T2DM) in the United Kingdom.

METHODS:

Using the IQVIA Core Diabetes Model, environmental and clinical impacts were projected over a lifetime horizon from the National Health Services perspective. Data from the SUSTAIN-2 (patients with T2DM) and SUSTAIN-6 (patients with T2DM and established cardiovascular [CV] risk) trials were used to compare semaglutide with sitagliptin and placebo, respectively. Outcomes included life expectancy measured in life-years (LYs) and quality-adjusted life expectancy measured in quality-adjusted life-years (QALYs) gained, incidence of diabetes-related complications and adverse events, carbon emissions, and incremental carbon footprint effectiveness ratios.

RESULTS:

In patients with T2DM, semaglutide dominates sitagliptin, with higher discounted LYs (0.096) and QALYs (0.095) gains, a 6.9% reduction in diabetes-related complications and adverse events, and reduced lifetime carbon emissions by 9.3% (13,899 kg carbon dioxide equivalent emissions [CO₂e] versus 15,319 kg CO₂e). Similarly, in patients with T2DM and established CV risk, semaglutide showed higher discounted LYs (0.206) and QALYs (0.164), with reductions in all complications except heart failure-related hospitalizations versus placebo. Lifetime carbon emissions were 5.2% lower with semaglutide (14,546 kg CO₂e versus 15,341 kg CO₂e), again with a dominant carbon footprint effectiveness ratio. The reduction in CO₂ was mainly driven by reduced complications and treatment needs. Sensitivity analyses supported the robustness of the results.

CONCLUSION:

Semaglutide offers environmental advantages over sitagliptin for patients with T2DM overall and over standard of care for those with established CV risk.

786

项与西格列汀相关的新闻（医药）

2026-10-09

·今日头条

ED药物遭遇“中年危机”

2026年，抗ED药物市场正经历一场深刻的格局重塑。曾经定义了一个时代的“伟哥”们集体遭遇中年危机——万艾可持续萎缩，希爱力被礼来剥离，国产仿制药金戈陷入量价齐跌困局。与此同时，国产1类创新药盐酸妥诺达非片获批上市，再生医学疗法进入临床验证，GLP-1类药物对勃起功能的影响引发学术争议。当老药走到命运分野的路口，ED药物研发的下一个十年属于谁？ 01 百年老药的「中年危机」 PDE5抑制剂的产业变迁，完整演绎了ED治疗药物从外资垄断、国产替代，再到群雄混战的商业演化路径。自万艾可问世之后，PDE5抑制剂长期占据ED治疗一线地位。公开数据显示，2022年全球PDE5抑制剂市场估值约31.7亿美元，预计以7.2%的年复合增长率持续扩张至2030年。在市场总量增长的表象之下，行业内部结构性矛盾暗流涌动。国内市场格局的重塑极具行业样本意义。辉瑞万艾可在专利到期之后，持续承受仿制药冲击，市场规模不断萎缩；礼来希爱力逐步从集团核心资产转为被剥离的非核心业务，2024年希爱力在药店和网店渠道合计销售额约9.35亿元，院外市场成为其主要阵地。曾经作为国产首仿标杆的白云山金戈，凭借低价策略一度登顶国内市场，但是在大量竞品涌入的仿制药内卷环境下，已经连续两年陷入“量价齐跌”的困局。仿制药大规模上市极大释放了药物可及性。国产仿制药把单片制剂价格从原研80-120元下探至3-5元区间，患者月均用药成本不足进口原研药的十分之一。价格弹性释放带动市场扩容，2025年国内抗ED药物整体市场规模达到114.6亿元，2019-2025年年复合增长率达17.8%。需要客观认识，这一轮市场增长并不简单等同于国产替代，更多是过去被高价压抑的真实临床消费需求得到集中释放。单纯价格战的天花板已经显现，国产创新药开始尝试依靠临床价值差异化跳出价格战泥潭。扬子江药业自主1类创新药盐酸妥诺达非片2025年7月获国家药监局批准，2026年6月全面上市。该品种通过分子结构优化，提升靶点抑制活性与选择性，在保证疗效前提下，受食物、饮酒干扰更小，用药场景更加灵活，标志着国内PDE5抑制剂赛道正式告别单纯仿制，迈入自主创新阶段。值得注意的是，就在PDE5抑制剂市场陷入存量博弈的同时，另一类药物——GLP-1受体激动剂——正在以“跨界者”的姿态进入研究者视野。2026年9月《自然》杂志刊登的一项研究显示，司美格鲁肽能够延长老年雌性小鼠的寿命并改善认知功能。这不禁让人追问：这类在代谢领域大放异彩的药物，能否为ED治疗带来新的可能？ 02 下一代ED药物的技术竞赛传统PDE5抑制剂市场逐步趋于饱和，全球下一代ED治疗研发在多条技术路线同步推进，研发目标不再局限于临时改善勃起，一部分管线着眼病理组织修复，另一部分开发替代递送途径，基础研究层面也在持续挖掘全新先导分子。再生医学疗法主打“修复而非替代”的治疗理念。传统口服药物只能临时调控局部血流，无法修复已经受损的血管内皮和外周神经组织。2026年《World Journal of Urology》发表的一项前瞻性研究纳入48名血管源性ED患者，接受12次径向型低强度体外冲击波治疗（Li-ESWT）。结果显示，6个月时43.8%的患者达到临床有意义的勃起功能改善，IIEF-EF和EHS评分均显著提升（p<0.001）。研究还发现，既往对PDE5抑制剂有应答的患者从Li-ESWT中获益的可能性更高（OR 5.59，95%CI 1.24-25.23）。但该类疗法仍然存在样本规模有限、标准化治疗方案尚未统一、长期随访证据不足等短板，距离大规模标准化临床普及仍有距离。如果说再生医学试图从根本上修复ED的病理基础，那么对于口服药物不耐受或应答不佳的患者，改进给药途径则是另一条更为务实的研发思路。针对口服药物不耐受、应答不佳的人群，全新剂型与递送途径成为重要研发方向。2026年5月正式启动的一项II期临床试验（NCT07601646），评估尿道内给药的前列地尔糊剂ST-04。该制剂给药后可在尿道内分散并形成水凝胶粘附于尿道内壁，旨在促进阴茎充血勃起。这项单臂剂量递增研究设置三个剂量水平，同时评估制剂和西地那非联合使用的潜在价值，为口服药物效果有限的患者提供局部给药的备选方案。联合治疗策略同样成为研发热点。2026年9月启动的PLEASURE试验探索“器械+药物”的组合思路，将Eroxon凝胶与他达拉非联合使用，针对18-40岁合并2型糖尿病的ED患者。这项随机对照试验以IIEF-5评分变化作为主要终点，同时评估患者用药依从性以及伴侣接受度。该试验的设计思路，也反映出ED治疗正在从单一药物干预，向综合化、个体化治疗方案演进。在基础研究层面，天然产物为新型PDE5抑制剂开发提供新方向。2026年8月发表于《Journal of Molecular Modeling》的研究，借助分子对接技术，评估了从Veronica anagallis-aquatica中分离得到的8种环烯醚萜苷的PDE5抑制活性。研究重点关注化合物对PDE6的选择性，PDE6被普遍认为是现有PDE5抑制剂诱发视觉异常“蓝视”副作用的重要诱因。如果能够筛选得到高选择性作用于PDE5、对PDE6抑制作用微弱的先导化合物，有望从源头减轻这类药物的视觉相关不良反应。当然，从分子对接的体外结果到临床药物落地，仍然需要大量药理、药效与成药性评价工作。 03 GLP-1与ED的复杂关系：是友还是敌？回到开头提到的司美格鲁肽抗衰研究，一个值得追问的问题是：如果GLP-1受体激动剂能够延缓衰老相关的病理进程，那么它是否也能影响勃起功能？这个问题并非空穴来风——勃起功能障碍与血管衰老、神经退行性改变之间存在明确的病理关联，阴茎海绵体内皮功能障碍与全身血管老化共享内皮功能障碍、氧化应激、慢性炎症等多种病理通路。然而，当研究者真正将目光从“抗衰”转向“勃起功能”时，现有科研证据却呈现出相互矛盾的图景。 GLP-1受体激动剂是近年来医药行业最受关注的药物类别，其在糖尿病、肥胖、心血管保护领域的多重获益已经得到大量临床证实。但当研究者将目光投向勃起功能障碍，现有科研证据却呈现出相互矛盾的图景，留给临床诸多待解答的疑问。支持GLP-1具备潜在正向作用的证据主要来自动物实验。2016年《中华男科学杂志》一篇动物研究表明，利拉鲁肽可以通过调控Akt/eNOS信号通路，保护糖尿病ED模型大鼠的阴茎海绵体内皮细胞功能，改善动物勃起相关指标。2025年发表在《Biomolecules》的综述进一步梳理现有文献，提出GLP-1受体激动剂具备多效药理作用，理论上对勃起功能存在潜在获益，这一假设也得到越来越多动物与小规模临床研究的间接支撑。但是来自药物警戒数据库的信号，却给出完全不同的观察视角。2026年《Andrology》刊载一项基于FDA不良事件报告系统（FAERS）的不均衡性分析，对比司美格鲁肽、西格列汀、达格列净等数款降糖药物与ED不良事件的关联。分析显示司美格鲁肽相关ED上报共计49例，46.9%报告人群集中在18-64岁，超过70%报告时间集中于2022-2024年。面对这种正反证据并存的局面，行业提出数种可能性解释：GLP-1受体激动剂带来的快速体重下降，可能造成部分患者体内相对性雄激素水平波动；药物常见胃肠道不良反应，间接降低性欲与性功能；也有可能该类报告仅仅是因为肥胖、糖尿病人群本身ED基线患病率就显著偏高，属于背景噪声，并非药物直接导致的不良反应。正如2025年该篇综述总结，目前全部证据尚不足以得出确定性因果结论，亟需更多前瞻性临床队列研究厘清GLP-1受体激动剂对勃起功能的真实影响。这一议题拥有明确现实临床意义。随着GLP-1类药物在糖尿病、肥胖人群大规模普及，性功能相关变化，已经成为医生与患者共同关心的生活质量终点。该案例也提示，对一款药物开展获益-风险评估，不能仅仅聚焦血糖、体重等硬生化指标，同样需要重视患者生活质量层面的各类结局。 04 结语 ED药物的2026年，是一个旧秩序瓦解、新格局未定的转折时刻。PDE5抑制剂市场从蓝海走向红海，国产创新药试图用临床价值突围；再生医学和新递送途径为难治性患者带来希望；GLP-1类药物与勃起功能的复杂关系仍在探索。当“伟哥”们集体迎来中年危机，下一个定义时代的药物会是什么？答案或许就在正在进行的那数百项临床试验中。注：本文仅作信息交流之目的，文中观点不代表药智网立场，也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。参考来源： 1.《2026中国抗ED药物行业白皮书》，2026年8月 2.Feng Y,Barthez M,Wang Y,et al.Late-life semaglutide treatment slows ageing and extends lifespan in female mice.Nature.2026.DOI:10.1038/s41586-026-10940-7 3.Kounatidis D,Vallianou NG,Rebelos E,et al.The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function:Friend or Foe?Biomolecules.2025;15(9):1284.DOI:10.3390/biom15091284 4.Sexual Safety Signals of Common Antidiabetic Drugs:Insights From FAERS Disproportionality Analysis.Andrology.2026.DOI:10.1111/andr.70222 5.World Journal of Urology.2026. 6.中华男科学杂志.2016.PMID:27172659 7.ClinicalTrials.gov:NCT07601646 8.ClinicalTrials.gov:NCT07636161 图片来源：摄图网声明：本内容仅用作医药行业信息传播，为作者独立观点，不代表药智网立场。如需转载，请务必注明文章作者和来源。

2026-10-09

·百度百家

ED药物遭遇“中年危机”

2026年，抗ED药物市场正经历一场深刻的格局重塑。曾经定义了一个时代的“伟哥”们集体遭遇中年危机——万艾可持续萎缩，希爱力被礼来剥离，国产仿制药金戈陷入量价齐跌困局。与此同时，国产1类创新药盐酸妥诺达非片获批上市，再生医学疗法进入临床验证，GLP-1类药物对勃起功能的影响引发学术争议。当老药走到命运分野的路口，ED药物研发的下一个十年属于谁？ 01 百年老药的「中年危机」 PDE5抑制剂的产业变迁，完整演绎了ED治疗药物从外资垄断、国产替代，再到群雄混战的商业演化路径。自万艾可问世之后，PDE5抑制剂长期占据ED治疗一线地位。公开数据显示，2022年全球PDE5抑制剂市场估值约31.7亿美元，预计以7.2%的年复合增长率持续扩张至2030年。在市场总量增长的表象之下，行业内部结构性矛盾暗流涌动。国内市场格局的重塑极具行业样本意义。辉瑞万艾可在专利到期之后，持续承受仿制药冲击，市场规模不断萎缩；礼来希爱力逐步从集团核心资产转为被剥离的非核心业务，2024年希爱力在药店和网店渠道合计销售额约9.35亿元，院外市场成为其主要阵地。曾经作为国产首仿标杆的白云山金戈，凭借低价策略一度登顶国内市场，但是在大量竞品涌入的仿制药内卷环境下，已经连续两年陷入“量价齐跌”的困局。仿制药大规模上市极大释放了药物可及性。国产仿制药把单片制剂价格从原研80-120元下探至3-5元区间，患者月均用药成本不足进口原研药的十分之一。价格弹性释放带动市场扩容，2025年国内抗ED药物整体市场规模达到114.6亿元，2019-2025年年复合增长率达17.8%。需要客观认识，这一轮市场增长并不简单等同于国产替代，更多是过去被高价压抑的真实临床消费需求得到集中释放。单纯价格战的天花板已经显现，国产创新药开始尝试依靠临床价值差异化跳出价格战泥潭。扬子江药业自主1类创新药盐酸妥诺达非片2025年7月获国家药监局批准，2026年6月全面上市。该品种通过分子结构优化，提升靶点抑制活性与选择性，在保证疗效前提下，受食物、饮酒干扰更小，用药场景更加灵活，标志着国内PDE5抑制剂赛道正式告别单纯仿制，迈入自主创新阶段。值得注意的是，就在PDE5抑制剂市场陷入存量博弈的同时，另一类药物——GLP-1受体激动剂——正在以“跨界者”的姿态进入研究者视野。2026年9月《自然》杂志刊登的一项研究显示，司美格鲁肽能够延长老年雌性小鼠的寿命并改善认知功能。这不禁让人追问：这类在代谢领域大放异彩的药物，能否为ED治疗带来新的可能？ 02 下一代ED药物的技术竞赛传统PDE5抑制剂市场逐步趋于饱和，全球下一代ED治疗研发在多条技术路线同步推进，研发目标不再局限于临时改善勃起，一部分管线着眼病理组织修复，另一部分开发替代递送途径，基础研究层面也在持续挖掘全新先导分子。再生医学疗法主打“修复而非替代”的治疗理念。传统口服药物只能临时调控局部血流，无法修复已经受损的血管内皮和外周神经组织。2026年《World Journal of Urology》发表的一项前瞻性研究纳入48名血管源性ED患者，接受12次径向型低强度体外冲击波治疗（Li-ESWT）。结果显示，6个月时43.8%的患者达到临床有意义的勃起功能改善，IIEF-EF和EHS评分均显著提升（p<0.001）。研究还发现，既往对PDE5抑制剂有应答的患者从Li-ESWT中获益的可能性更高（OR 5.59，95%CI 1.24-25.23）。但该类疗法仍然存在样本规模有限、标准化治疗方案尚未统一、长期随访证据不足等短板，距离大规模标准化临床普及仍有距离。如果说再生医学试图从根本上修复ED的病理基础，那么对于口服药物不耐受或应答不佳的患者，改进给药途径则是另一条更为务实的研发思路。针对口服药物不耐受、应答不佳的人群，全新剂型与递送途径成为重要研发方向。2026年5月正式启动的一项II期临床试验（NCT07601646），评估尿道内给药的前列地尔糊剂ST-04。该制剂给药后可在尿道内分散并形成水凝胶粘附于尿道内壁，旨在促进阴茎充血勃起。这项单臂剂量递增研究设置三个剂量水平，同时评估制剂和西地那非联合使用的潜在价值，为口服药物效果有限的患者提供局部给药的备选方案。联合治疗策略同样成为研发热点。2026年9月启动的PLEASURE试验探索“器械+药物”的组合思路，将Eroxon凝胶与他达拉非联合使用，针对18-40岁合并2型糖尿病的ED患者。这项随机对照试验以IIEF-5评分变化作为主要终点，同时评估患者用药依从性以及伴侣接受度。该试验的设计思路，也反映出ED治疗正在从单一药物干预，向综合化、个体化治疗方案演进。在基础研究层面，天然产物为新型PDE5抑制剂开发提供新方向。2026年8月发表于《Journal of Molecular Modeling》的研究，借助分子对接技术，评估了从Veronica anagallis-aquatica中分离得到的8种环烯醚萜苷的PDE5抑制活性。研究重点关注化合物对PDE6的选择性，PDE6被普遍认为是现有PDE5抑制剂诱发视觉异常“蓝视”副作用的重要诱因。如果能够筛选得到高选择性作用于PDE5、对PDE6抑制作用微弱的先导化合物，有望从源头减轻这类药物的视觉相关不良反应。当然，从分子对接的体外结果到临床药物落地，仍然需要大量药理、药效与成药性评价工作。 03 GLP-1与ED的复杂关系：是友还是敌？回到开头提到的司美格鲁肽抗衰研究，一个值得追问的问题是：如果GLP-1受体激动剂能够延缓衰老相关的病理进程，那么它是否也能影响勃起功能？这个问题并非空穴来风——勃起功能障碍与血管衰老、神经退行性改变之间存在明确的病理关联，阴茎海绵体内皮功能障碍与全身血管老化共享内皮功能障碍、氧化应激、慢性炎症等多种病理通路。然而，当研究者真正将目光从“抗衰”转向“勃起功能”时，现有科研证据却呈现出相互矛盾的图景。 GLP-1受体激动剂是近年来医药行业最受关注的药物类别，其在糖尿病、肥胖、心血管保护领域的多重获益已经得到大量临床证实。但当研究者将目光投向勃起功能障碍，现有科研证据却呈现出相互矛盾的图景，留给临床诸多待解答的疑问。支持GLP-1具备潜在正向作用的证据主要来自动物实验。2016年《中华男科学杂志》一篇动物研究表明，利拉鲁肽可以通过调控Akt/eNOS信号通路，保护糖尿病ED模型大鼠的阴茎海绵体内皮细胞功能，改善动物勃起相关指标。2025年发表在《Biomolecules》的综述进一步梳理现有文献，提出GLP-1受体激动剂具备多效药理作用，理论上对勃起功能存在潜在获益，这一假设也得到越来越多动物与小规模临床研究的间接支撑。但是来自药物警戒数据库的信号，却给出完全不同的观察视角。2026年《Andrology》刊载一项基于FDA不良事件报告系统（FAERS）的不均衡性分析，对比司美格鲁肽、西格列汀、达格列净等数款降糖药物与ED不良事件的关联。分析显示司美格鲁肽相关ED上报共计49例，46.9%报告人群集中在18-64岁，超过70%报告时间集中于2022-2024年。面对这种正反证据并存的局面，行业提出数种可能性解释：GLP-1受体激动剂带来的快速体重下降，可能造成部分患者体内相对性雄激素水平波动；药物常见胃肠道不良反应，间接降低性欲与性功能；也有可能该类报告仅仅是因为肥胖、糖尿病人群本身ED基线患病率就显著偏高，属于背景噪声，并非药物直接导致的不良反应。正如2025年该篇综述总结，目前全部证据尚不足以得出确定性因果结论，亟需更多前瞻性临床队列研究厘清GLP-1受体激动剂对勃起功能的真实影响。这一议题拥有明确现实临床意义。随着GLP-1类药物在糖尿病、肥胖人群大规模普及，性功能相关变化，已经成为医生与患者共同关心的生活质量终点。该案例也提示，对一款药物开展获益-风险评估，不能仅仅聚焦血糖、体重等硬生化指标，同样需要重视患者生活质量层面的各类结局。 04 结语 ED药物的2026年，是一个旧秩序瓦解、新格局未定的转折时刻。PDE5抑制剂市场从蓝海走向红海，国产创新药试图用临床价值突围；再生医学和新递送途径为难治性患者带来希望；GLP-1类药物与勃起功能的复杂关系仍在探索。当“伟哥”们集体迎来中年危机，下一个定义时代的药物会是什么？答案或许就在正在进行的那数百项临床试验中。注：本文仅作信息交流之目的，文中观点不代表药智网立场，也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。参考来源： 1.《2026中国抗ED药物行业白皮书》，2026年8月 2.Feng Y,Barthez M,Wang Y,et al.Late-life semaglutide treatment slows ageing and extends lifespan in female mice.Nature.2026.DOI:10.1038/s41586-026-10940-7 3.Kounatidis D,Vallianou NG,Rebelos E,et al.The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function:Friend or Foe?Biomolecules.2025;15(9):1284.DOI:10.3390/biom15091284 4.Sexual Safety Signals of Common Antidiabetic Drugs:Insights From FAERS Disproportionality Analysis.Andrology.2026.DOI:10.1111/andr.70222 5.World Journal of Urology.2026. 6.中华男科学杂志.2016.PMID:27172659 7.ClinicalTrials.gov:NCT07601646 8.ClinicalTrials.gov:NCT07636161 图片来源：摄图网声明：本内容仅用作医药行业信息传播，为作者独立观点，不代表药智网立场。如需转载，请务必注明文章作者和来源。

2026-10-08

·PRNewswire

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market to Reach USD 15,527.66 Million by 2032 - Credence Research

LONDON, Oct. 8, 2026 /PRNewswire/ -- The "Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market – Growth, Share, Opportunities & Competitive Analysis, 2026–2032" report has been added to the Credence Research Inc. offering. The global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market was valued at USD 11,280.60 million in 2025 and is projected to reach USD 15,527.66 million by 2032, registering a CAGR of 5.47%. Demand is supported by the persistent global burden of type 2 diabetes, continued use of oral glucose-lowering therapies and the expanding availability of generics and fixed-dose combinations. DPP-4 inhibitors remain relevant for selected patients who benefit from simple oral dosing, low hypoglycemia risk and weight-neutral treatment profiles, although newer incretin and cardiometabolic therapies are increasing competitive pressure. Key Takeaways The market is projected to rise from USD 11,280.60 million in 2025 to USD 15,527.66 million by 2032 at a CAGR of 5.47%. Sitagliptin led the drug type segment with a 36.9% share in 2025, supported by long-standing prescribing familiarity, broad availability and generic participation. Retail pharmacies accounted for 44.8% of 2025 revenue, reflecting repeat-refill behavior in chronic outpatient diabetes management. North America led with a 37.8% share in 2025, followed by Europe at 26.1% and Asia Pacific at 23.4%. Fixed-dose combinations with metformin remain strategically important because they can reduce pill burden and support stepwise treatment intensification. Validated core participants include Merck & Co., AstraZeneca, Boehringer Ingelheim, Takeda Pharmaceutical, Novartis, Eli Lilly, Lupin, Sun Pharmaceutical and Dr. Reddy's Laboratories. Scope & Segmentation – Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market The report provides a comprehensive analysis of the global DPP-4 Inhibitors Market through 2032, covering drug molecules, formulation formats, treatment sequencing, combination strategies, dispensing channels and patient groups. The study evaluates how generic entry, payer formularies, fixed-dose combinations and competition from GLP-1, dual incretin and SGLT2 therapies are reshaping commercial strategies. It also examines regional access, chronic refill infrastructure and molecule-level considerations that influence prescribing. The DPP-4 Inhibitors Market is segmented based on drug type, formulation, therapy line, combination type, distribution channel, patient type and geography. By Drug Type, the market includes Sitagliptin, Saxagliptin, Linagliptin, Alogliptin and Others. By Formulation, the market includes Oral Tablets, Fixed-dose Combinations and Others. By Therapy Line, the market includes First-line Therapy, Second-line Therapy, Add-on Therapy and Others. By Combination Type, the market includes Monotherapy, Combination with Metformin, Combination with SGLT2 and Others. By Distribution Channel, the market includes Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. By Patient Type, the market includes Type 2 Diabetes Adults, Elderly Patients, Renal-impaired Patients and Others. By Geography, the market is analyzed across North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Access crucial information at unmatched prices! Request your sample report today and start making informed decisions powered by Credence Research Inc. Why This Report Matters The report provides a focused view of a mature but resilient oral diabetes drug class undergoing a transition from branded growth toward access-led generic volume. It helps decision-makers assess molecule-level demand, fixed-dose combination opportunities, distribution dynamics and evolving therapy-line positioning. The study highlights the commercial impact of newer diabetes classes that offer weight-loss or broader cardiometabolic benefits. For pharmaceutical manufacturers, generic drug companies, distributors and investors, the report provides actionable intelligence for portfolio, pricing and market-access decisions. Market Overview • Industry Landscape and Value Chain Assessment • Supply-Side Evaluation • Demand-Side Evaluation • Stakeholder Mapping • Porter's Five Forces Review • PESTLE Environment Assessment • Market Forecast and Future Direction • Short-Term Forecast, 0–2 Years • Mid-Term Forecast, 3–5 Years • Long-Term Forecast, 5–10 Years • Market Entry and Expansion Strategy Market Insights • Patient and Prescriber Analysis • Therapy Sequencing Assessment • Generic Entry and Substitution Review • Fixed-Dose Combination Opportunity Assessment • Distribution and Refill Channel Review • Pricing and Reimbursement Analysis • Competitive Class Substitution Assessment • Regional Access and Diagnosis Review • Lifecycle Management and Portfolio Strategy Key Attributes Segmentation By Drug Type • Sitagliptin • Saxagliptin • Linagliptin • Alogliptin • Others By Formulation • Oral Tablets • Fixed-dose Combinations • Others By Therapy Line • First-line Therapy • Second-line Therapy • Add-on Therapy • Others By Combination Type • Monotherapy • Combination with Metformin • Combination with SGLT2 • Others By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • Others By Patient Type • Type 2 Diabetes Adults • Elderly Patients • Renal-impaired Patients • Others By Geography • North America • Europe • Asia Pacific • Latin America • Middle East & Africa Market Growth Driven by Chronic Type 2 Diabetes Demand and Oral Therapy Preference The persistent global burden of type 2 diabetes supports recurring demand for oral glucose-lowering medicines. DPP-4 inhibitors retain a role in selected patients because they offer simple daily administration, a generally low risk of hypoglycemia and a weight-neutral profile. These characteristics can be valuable in older patients, people managing multiple medicines and treatment plans where tolerability is prioritized. Generic entry is changing the revenue mix. Loss of exclusivity has reduced branded pricing power in several markets, yet lower-cost sitagliptin and other molecules can expand access and preserve prescription volume. Wider retail pharmacy availability and e-pharmacy distribution also support continuity for chronic therapy users. Fixed-dose combinations remain an important lifecycle strategy. Pairing DPP-4 inhibitors with metformin or other oral agents can simplify regimens and support patients who require stepwise treatment intensification without moving immediately to injectable therapy. Competitive Pressure from Newer Diabetes Therapies Reshapes the Market DPP-4 inhibitors face stronger competition from GLP-1 receptor agonists, dual incretin therapies and SGLT2 inhibitors. These newer classes can offer weight reduction or broader cardiovascular and renal benefits in selected patient populations, which can influence guideline positioning and payer preference. This pressure makes affordability, tolerability, oral convenience and combination availability increasingly important sources of differentiation. Manufacturers must manage mature brands carefully while generic suppliers compete on price, supply reliability and pharmacy coverage. Regional Growth Reflects Reimbursement Depth and Expanding Access North America led the market with a 37.8% share in 2025, supported by established diagnosis pathways, structured reimbursement and a mature retail refill infrastructure. Europe accounted for 26.1%, where reference pricing and cost-containment policies accelerate generic uptake while preserving steady outpatient use. Asia Pacific represented 23.4% of the market and offers substantial volume potential due to large diabetes populations, improving diagnosis and expanding pharmacy access. Latin America and Middle East & Africa remain smaller in revenue terms, with growth dependent on affordability, distributor reach and reimbursement development. Future Outlook The DPP-4 inhibitor market is expected to expand steadily rather than rapidly through 2032. Growth will be supported by chronic disease prevalence, generic access and fixed-dose combinations, while class share will remain under pressure from newer therapies with stronger weight and cardiometabolic profiles. Companies with broad generic portfolios, strong local distribution and combination-product capabilities will be better positioned to defend volume. Market opportunities will increasingly center on affordability, emerging-market access and simplified regimens rather than premium pricing. Competitive Landscape Competition is shifting from brand exclusivity toward formulary placement, generic substitution, combination availability and supply reliability. Merck remains closely associated with sitagliptin, while AstraZeneca, Boehringer Ingelheim, Takeda and Novartis have established DPP-4 portfolios or legacy brands. Eli Lilly remains relevant through its long-standing collaboration with Boehringer Ingelheim around linagliptin. Generic manufacturers including Lupin, Sun Pharmaceutical and Dr. Reddy's Laboratories strengthen price competition and expand access in large emerging markets. The strongest commercial positions increasingly depend on distribution coverage, procurement competitiveness and the ability to sustain reliable supply after patent expiry. Key Player Analysis • Merck & Co. • AstraZeneca • Boehringer Ingelheim • Takeda Pharmaceutical • Novartis • Eli Lilly and Company • Lupin • Sun Pharmaceutical • Dr. Reddy's Laboratories Recent Industry Developments In June 2025, Abbott and MSD Pharmaceuticals announced a distribution agreement in India covering sitagliptin, sitagliptin/metformin and the extended-release combination, expanding access to MSD's established DPP-4 portfolio. In January 2025, CSPC Pharmaceutical Group announced that China's National Medical Products Administration granted marketing approval for prusogliptin tablets, a new DPP-4 inhibitor for adults with type 2 diabetes. Report Coverage The research report offers an in-depth analysis based on Drug Type, Formulation, Therapy Line, Combination Type, Distribution Channel, Patient Type and Geography. It assesses market size, regional demand, competitive positioning, generic entry, fixed-dose combinations, reimbursement dynamics and the impact of alternative diabetes drug classes. The study provides strategic recommendations for branded manufacturers, generic companies, distributors and investors navigating a mature therapeutic category with changing treatment preferences. Access crucial information at unmatched prices! Request your sample report today and start making informed decisions powered by Credence Research Inc. Shape Your Report to Specific Countries or Regions and Enjoy 30% Off! Customize Now Related Reports – About Us Credence Research Inc is a global market intelligence and consulting firm founded in 2015. It delivers deep market insights, quantitative analysis, and strategic guidance to business leaders, investors, governments, NGOs, and non-profit groups worldwide. The company helps organizations evaluate markets, understand trends, reduce risk, and make data-driven decisions that support growth and competitive strategy. Credence Research is known for rigorous research methods and comprehensive analytics. The firm produces detailed reports covering market size, forecasts, growth drivers, trends, and competitive landscapes across many industries. Each report often includes frameworks like PESTLE and Porter's Five Forces to give a complete view of market dynamics and future potential. Credence Research also provides tailored consulting services, due diligence support, go-to-market planning, and pre-IPO research to strengthen client strategies and investment narratives. Its insights come from both primary and secondary research, expert interviews, and advanced data modelling. The firm's client base spans Europe, the Americas, Asia-Pacific, and the Middle East/Africa. To find out more, visit or follow us on X.com, LinkedIn and Facebook Contact Us – Credence Research Inc, Tower C-1105, S 25, Akash Tower, Vishal Nagar, Pimple Nilakh, Haveli, Pune – 411027, India USA: +1 6282 627 656 UK: +44 7453 598 606 Email: [email protected] Visit Our Website: SOURCE Credence Research Inc. 21% more press release views with Request a Demo

上市批准

100 项与西格列汀相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	美国	Zydus Lifesciences Ltd.	2023-10-18

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
杜氏肌营养不良症	临床前	美国	Revio Therapeutics LLP	2026-01-24
瘢痕	临床前	中国	中国人民解放军总医院	2025-10-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06115460 (Pubmed \| Diabetologia)	临床3期	1型糖尿病 \| 糖尿病肾病追加 SDF-1 levels	46	Sitagliptin 50 mg	襯淵鏇壓築願積鏇遞淵(鹽醖淵鬱簾糧觸艱顧網) = 餘餘糧餘簾網糧淵鏇廠憲艱淵選糧積簾鑰簾遞 (衊齋襯構範鬱艱鹽繭餘 ) 更多	积极	2024-09-14
				sitagliptin (AHCL only)	襯淵鏇壓築願積鏇遞淵(鹽醖淵鬱簾糧觸艱顧網) = 範鹹淵夢遞糧築壓夢廠憲艱淵選糧積簾鑰簾遞 (衊齋襯構範鬱艱鹽繭餘 )
1340-P (ADA2024)	N/A	糖尿病	-	SGLT2i	構繭獵糧窪壓憲鹹鹽鹽(觸憲蓋鹽鏇壓積鹽糧壓) = 餘醖憲醖鹹窪醖鹹淵壓鹹範壓觸餘繭遞顧積鑰 (範選餘鹽顧窪鏇淵鬱網, 16.6 ~ 19.7)	积极	2024-06-14
				DPP4i	構繭獵糧窪壓憲鹹鹽鹽(觸憲蓋鹽鏇壓積鹽糧壓) = 繭選遞築廠襯觸膚願範鹹範壓觸餘繭遞顧積鑰 (範選餘鹽顧窪鏇淵鬱網, 19.1 ~ 21.4)
FDA 人工标引	N/A	2型糖尿病	1,091	Placebo	蓋築鑰築夢製齋範簾製(餘醖齋鹹齋築獵糧構範) = 廠膚鹹憲網窪齋顧夢觸遞繭窪醖夢顧醖壓窪顧 (夢廠鑰繭鬱繭壓餘醖鏇 ) 更多	积极	2023-11-03
				Sitagliptin 100 mg	蓋築鑰築夢製齋範簾製(餘醖齋鹹齋築獵糧構範) = 選餘鹹選艱夢顧蓋觸齋遞繭窪醖夢顧醖壓窪顧 (夢廠鑰繭鬱繭壓餘醖鏇 ) 更多
FDA 人工标引	N/A	2型糖尿病	701	Sitagliptin 100 mg + Metformin	壓遞艱廠醖顧餘夢範醖(憲衊網壓遞鹹積鹹壓夢) = 餘醖膚膚憲繭築淵壓顧構窪壓廠網鬱積製構鑰 (觸網繭遞選願窪鏇膚築 ) 更多	积极	2023-11-03
				Placebo + Metformin	壓遞艱廠醖顧餘夢範醖(憲衊網壓遞鹹積鹹壓夢) = 願憲窪構網積窪餘築製構窪壓廠網鬱積製構鑰 (觸網繭遞選願窪鏇膚築 ) 更多
NCT01760447 (MK-0431A-170 \| MK-0431A-289, Pubmed \| Pediatr Diabetes) 人工标引	临床3期	2型糖尿病	220	Metformin+Insulin+Sitagliptin	淵膚範廠廠製製構襯憲(積憲製衊壓觸鏇願鹹鑰) = 鹹鬱鹽廠選簾窪網願積憲範壓鹽蓋積鹹繭獵蓋 (構積範遞選憲壓網積構, -0.94 ~ -0.22) 更多	不佳	2021-11-14
				Metformin+Insulin+Placebo	淵膚範廠廠製製構襯憲(積憲製衊壓觸鏇願鹹鑰) = 築遞範醖壓繭觸繭鑰築憲範壓鹽蓋積鹹繭獵蓋 (構積範遞選憲壓網積構, -0.43 ~ 0.26) 更多
NCT00790205 (TECOS, Pubmed \| Diabetes Care)	临床3期	2型糖尿病 \| 动脉粥样硬化	-	Sitagliptin	餘憲鹹蓋艱淵襯衊鬱餘(製夢壓獵糧鬱壓醖蓋製) = 餘襯鏇網製構艱夢築窪簾窪網餘壓鏇構願夢蓋 (鑰鏇醖衊繭餘積鬱夢餘 ) 更多	-	2017-12-01
				Placebo	壓遞製糧鏇繭艱願構範(艱選網醖憲鹽選選鏇鏇) = 廠襯鬱繭憲憲鑰鬱獵夢鹽窪餘製構齋廠簾窪願 (衊構鹽選壓網餘範網齋 )
NCT01183104 (START-J, CTgov)	N/A	2型糖尿病	305	Sitagliptin (Sitagliptin)	膚繭窪醖淵選觸夢繭鑰(選餘衊憲鏇鏇膚衊夢衊) = 齋齋壓膚選淵鹽簾淵齋觸膚窪選艱簾蓋顧願壓 (鹽鹹觸淵積觸繭鹹憲願, 簾範膚獵鏇醖選範構醖 ~ 衊鹽糧獵膚醖膚淵網範) 更多	-	2017-04-14
				Glimepiride (Glimepiride)	膚繭窪醖淵選觸夢繭鑰(選餘衊憲鏇鏇膚衊夢衊) = 齋衊積網餘構蓋築遞壓觸膚窪選艱簾蓋顧願壓 (鹽鹹觸淵積觸繭鹹憲願, 壓顧選構鬱醖選範構範 ~ 鏇鏇夢憲膚簾衊淵觸鬱) 更多
NCT00993187 (Pubmed \| J Diabetes)	临床4期	2型糖尿病	292	Sitagliptin/metformin fixed-dose combination	鏇範觸觸簾齋築夢襯積(範積餘簾鹽網鑰衊餘繭) = 夢窪獵積簾憲鹽網選鹹憲膚鏇範鏇觸繭襯糧餘 (鏇選鬱壓鏇願顧糧獵鹽 ) 更多	积极	2017-04-01
				Glimepiride	鏇範觸觸簾齋築夢襯積(範積餘簾鹽網鑰衊餘繭) = 範淵襯齋餘顧簾壓糧壓憲膚鏇範鏇觸繭襯糧餘 (鏇選鬱壓鏇願顧糧獵鹽 ) 更多
NCT00790205 (0431-082 \| TECOS, Pubmed \| Diabetes Care)	临床3期	-	14,671	Sitagliptin	鏇壓窪構夢鹹夢繭壓糧(獵淵積齋艱襯鏇餘窪醖) = 廠襯醖獵衊鑰觸範淵艱廠築蓋觸積壓鬱糧醖觸 (醖窪鬱範鏇遞獵遞窪醖 )	-	2017-04-01
				Placebo	鏇壓窪構夢鹹夢繭壓糧(獵淵積齋艱襯鏇餘窪醖) = 網衊襯鹽膚襯鏇窪夢觸廠築蓋觸積壓鬱糧醖觸 (醖窪鬱範鏇遞獵遞窪醖 )
NCT00790205 (0431-082 \| TECOS, Pubmed \| Diabetes Care)	临床3期	-	14,671	Sitagliptin	夢糧鏇淵鹽願積憲淵夢(醖遞鏇憲製築蓋鏇餘窪): hazard ratio = 0.66 (95% CI, 0.28 ~ 1.51), P-Value = 0.32 更多	-	2017-02-01
				Placebo